Compare RRR & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RRR | BLLN |
|---|---|---|
| Founded | 1976 | 2016 |
| Country | United States | United States |
| Employees | N/A | 713 |
| Industry | Hotels/Resorts | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.9B |
| IPO Year | 2015 | N/A |
| Metric | RRR | BLLN |
|---|---|---|
| Price | $61.27 | $103.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 7 |
| Target Price | $69.69 | ★ $126.71 |
| AVG Volume (30 Days) | ★ 776.8K | 708.8K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | ★ 23.32 | N/A |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $2,011,483,000.00 | N/A |
| Revenue This Year | $3.41 | $46.29 |
| Revenue Next Year | $4.62 | $30.14 |
| P/E Ratio | $81.01 | ★ N/A |
| Revenue Growth | ★ 3.74 | N/A |
| 52 Week Low | $50.03 | $61.96 |
| 52 Week High | $68.99 | $138.70 |
| Indicator | RRR | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 61.17 | 59.06 |
| Support Level | $59.80 | $79.07 |
| Resistance Level | $63.34 | $108.50 |
| Average True Range (ATR) | 1.83 | 7.70 |
| MACD | 0.16 | 0.14 |
| Stochastic Oscillator | 67.76 | 72.62 |
Red Rock Resorts Inc along with its subsidiary is a gaming, development and management company that develops and operates strategically-located casino and entertainment properties. Its casino properties are conveniently located throughout the Las Vegas valley and provide its customers a wide variety of entertainment and dining options. The majority of revenue is derived from Casinos, followed by Food and Beverages, Rooms and others.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.